(E)-4-{2-methyl-2-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-propionylamino}-adamantane-1-carboxylic acid | 896444-44-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: (E)-4-{2-methyl-2-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-propionylamino}-adamantane-1-carboxylic acid
• 英文别名: 4-[[2-methyl-2-[4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]propanoyl]amino]adamantane-1-carboxylic acid
• CAS: 896444-44-3
• 化学式: C₂₅H₃₃F₃N₄O₃
• 分子量: 494.557
• InChiKey: RVIKUVQZTJUNNT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  35
• 可旋转键数：
  5
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.72
• 拓扑面积：
  85.8
• 氢给体数：
  2
• 氢受体数：
  9

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  ——	methyl (E)-4-{2-methyl-2-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-propionylamino}-adamantane-1-carboxylate	868623-73-8	C26H35F3N4O3	508.584

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  ——	(E)-4-{2-methyl-2-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-propionylamino}-adamantane-1-carboxamide	868623-40-9	C25H34F3N5O2	493.572
  ——	N-[(E)-5-isocyanato-2-adamantyl]-2-methyl-2-{4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}propanamide	——	C25H32F3N5O2	491.557

反应信息

• 作为反应物：
  描述：

  (E)-4-{2-methyl-2-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-propionylamino}-adamantane-1-carboxylic acid 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 氨 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 21.0h， 生成 (E)-4-{2-methyl-2-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-propionylamino}-adamantane-1-carboxamide
  参考文献：
  名称：

  Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme

  摘要：

  本发明涉及抑制11-β-羟基类固醇脱氢酶1型酶的化合物。本发明还涉及利用11-β-羟基类固醇脱氢酶1型酶的抑制剂治疗非胰岛素依赖型2型糖尿病、胰岛素抵抗、肥胖、脂质紊乱、代谢综合征以及其他由过度糖皮质激素作用介导的疾病和症状。

  公开号：

  US20050277647A1
• 作为产物：
  描述：

  methyl (E)-4-{2-methyl-2-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-propionylamino}-adamantane-1-carboxylate 以98.0的产率得到(E)-4-{2-methyl-2-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-propionylamino}-adamantane-1-carboxylic acid
  参考文献：
  名称：

  Organic Process Research & Development 2008, 12, 1114–1118

  摘要：

  DOI：

文献信息

• Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
  申请人：Link T. James

  公开号：US20050277647A1

  公开（公告）日：2005-12-15

  The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.

  本发明涉及抑制11-β-羟基类固醇脱氢酶1型酶的化合物。本发明还涉及利用11-β-羟基类固醇脱氢酶1型酶的抑制剂治疗非胰岛素依赖型2型糖尿病、胰岛素抵抗、肥胖、脂质紊乱、代谢综合征以及其他由过度糖皮质激素作用介导的疾病和症状。
• NOVEL AMIDE AND AMIDINE DERIVATIVES AND USES THEREOF
  申请人：Peddi Sridhar

  公开号：US20100267738A1

  公开（公告）日：2010-10-21

  The present invention relates to inhibitors of 11-β-hydroxysteroid dehydrogenase type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.

  本发明涉及11-β-羟基类固醇脱氢酶类型1酶的抑制剂及其在治疗非胰岛素依赖型2型糖尿病、胰岛素抵抗、肥胖、脂质紊乱、代谢综合征、中枢神经系统疾病以及与过多糖皮质激素相关的疾病和病况中的应用。
• Metabolic stabilization of substituted adamantane
  申请人：Rohde J. Jeffrey

  公开号：US20060148871A1

  公开（公告）日：2006-07-06

  The present invention is directed to the method of increasing the metabolic stability of adamantane containing compounds that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 (11-beta-HSD-1) enzyme. The stability is achieved by substitutions of the adamantane ring.

  本发明涉及一种增加含有金刚烷基化合物代谢稳定性的方法，这些化合物是11-β-羟基类固醇脱氢酶1（11-β-HSD-1）酶的抑制剂。通过对金刚烷环进行取代实现稳定性。
• TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS
  申请人：Bitner R. Scott

  公开号：US20090054426A1

  公开（公告）日：2009-02-26

  A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-β-hydroxysteroid dehydrogenase Type 1 enzyme activity.

  一种治疗患有与糖尿病相关的中枢神经系统紊乱和缺陷的患者的方法，包括与衰老和神经退行性疾病相关的注意力缺陷障碍，注意力缺陷多动障碍（ADHD），阿尔茨海默病（AD），轻度认知障碍，老年性痴呆症，艾滋病痴呆，神经退行性疾病，抑郁症和精神分裂症，包括向需要此类治疗的患者施用11-β-羟基类固醇脱氢酶1型酶活性的选择性抑制剂的有效量。
• INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME
  申请人：Pliushchev Marina A.

  公开号：US20100222316A1

  公开（公告）日：2010-09-02

  The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.

  本发明涉及一种抑制11-beta-羟基类固醇脱氢酶1型酶的化合物。本发明还涉及使用11-beta-羟基类固醇脱氢酶1型酶的抑制剂治疗非胰岛素依赖性2型糖尿病、胰岛素抵抗、肥胖症、脂质代谢紊乱、代谢综合征和其他由过度糖皮质激素作用介导的疾病和病况。